Inogen (NSDQ:INGN) announced today that its board of directors appointed George Parr as its EVP and chief commercial officer.
Goleta, Calif.-based Inogen’s EVP of marketing, Byron Myers, and EVP of sales, Arron Retterer, announced earlier this month that they plan to leave Inogen, effective June 4, 2021, following a transition period. Parr will assume his role, effective April 12, 2021, according to a news release.
Parr most recently served as EVP & CMO at BD, holding the role from November 2017 through January 2020. He also served as SVP & CMO at SIRVA Worldwide Relocating & Moving from 2014 to 2017 and before that he held the role of SVP & CMO at Diversey.
“I am honored by the opportunity to lead the commercial operations of Inogen in our mission to increase the freedom and independence for respiratory patients and to make our technologies the standard of care,” Parr said in the release. “I look forward to contributing to the next phase of Inogen’s success as we continue to seek ways to increase patient access to our technologies, expand the impact we have on patients, drive growth, and increase value for our stockholders.”
Inogen also noted in the release that it expects total revenue for the first quarter of 2021 to range between $84 million and $87 million.
“On behalf of the board of directors, I would like to congratulate George on this appointment as I believe that he will be a tremendous asset to Inogen and a great addition to the executive team. We believe our path forward necessitates building on current strengths but adding new capabilities to deliver on our strategic imperatives,” Inogen CEO Nabil Shabshab said. “George’s 25 years of experience in C-suite, general management, marketing, and sales management roles across medical technology, consumer products, and industrial categories and markets around the world will be a great enabler in building a stronger Inogen and elevating our performance.
“I would like to thank Byron for his dedication and commitment to Inogen over the past twenty years that has helped increase patient awareness of our innovative, market-leading products, and creating a unique go-to-market approach. Additionally, I want to thank Arron for his contributions to Inogen’s success in the last year as we focused on increasing physician awareness and patient access to our products.”